Icosapent Ethyl Reduces MACE Across Range of Baseline Lp(a): REDUCE-IT Analysis
ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.
FDA Approves Aprocitentan for Treatment-Resistant HTN: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Issues Warning Letters to 6 Companies Marketing Misbranded OTC Topical Analgesics
Specifically, the topical analgesics, available over the counter, may contain higher than labeled concentrations of lidocaine, according to the agency.
Blood-Based DNA Test for Colorectal Cancer: Daily Dose
Remission from Type 2 Diabetes via Lifestyle Intervention Reduces Risk for CVD, CKD
Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.
COVID-19 Vaccines Reduce Risk of Cardiac, Thromboembolic Outcomes: Daily Dose
Moderna Next-Gen mRNA COVID-19 Vaccine Meets Primary Endpoints in NextCOVE Phase 3 Trial
The mRNA bivalent vaccine candidate produced a "more robust" immune response vs Spikevax and particularly in adults over the age of 65 years, said Moderna.
Viking Therapeutics Oral Antiobesity Agent Returns Positive Results in Small Study
The once daily tablet, VK2375, is headed to a phase 2 trial later this year and is an oral version of Viking's investigational injectable GLP-1/GIP mimetic currently in phase 2.
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
Sotagliflozin Impact on Stroke, MI to Be Explored in 4 Posters at ACC.24
The novel SGLT-2/SGLT-1 inhibitor reduced risk of stroke, MI, and demonstrates significant antiplatelet activity in post-hoc analyses of SCORED phase 3 trial.
New Data Shed Light on Disparities in Coronary Artery Calcium Screening
ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.
Remotely Delivered Lipid Lowering Program Results in Sustained Target LDL-C Levels in High-Risk Population
ACC.2024: In a cohort of people at high risk of ASCVD, three-quarters achieved target LDL-C levels at 6 months and 12 months while using a remote algorithm-directed program.
Tapinarof Cream 1.0% Effective for Atopic Dermatitis: Daily Dose
Concomitant SSRI and DOAC Use Increases Risk of Major Bleeding, Including ICH: New Findings
Overall, a 33% increased risk of major bleeding was seen, with risk highest during the first 30 days of concomitant use and persistent, but lower, after 6 months.
FDA Approves Fixed-Dose Macitentan/Tadalafil Tablets (Opsynvi) For Pulmonary Arterial Hypertension
For the first time, 2 drugs recommended as first line treatment for PAH are combined in a single oral once-daily therapy, which could reduced burden of care.
FDA Expands Bempedoic Acid Label to Include Primary, Secondary CV Risk Reduction, With or Without Statins
Bempedoic acid is now the only non-statin therapy indicated for primary CVD prevention, with potential to expand treatment access to millions, said Esperion Therapeutics.
Medicare Will Cover AOM Semaglutide for Cardiovascular Risk Reduction: A First
CMS says Medicare Part D plans will cover semaglutide for individuals with overweight/obesity who have preexisting CVD, a first after 40 years of legal prohibition.
Respiratory Virus Vaccines on Deck for 2024
Respiratory vaccine R & D at Moderna, Merck, and Pfizer is focused on mRNA technology, added protection for vulnerable populations, and combination shots.
Obesity and Venous Disease: Risk Factors and Key Diagnostic Challenges